Obesity in the spotlight (part IV)
Learning to separate hype from reality...
Last week, Boutique Biotech shared how weight-loss drugs might impact the various obesity-related markets. The hype craze has pushed additional data that is now being blown out of proportion. The bottom line is that big pharma, primarily Novo Nordisk and Eli Lilly, need to get weight-loss drugs on Medicare schedules for reimbursement. Billions of revenu…